TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06721143: A Study to Investigate the Safety, Tolerability, and Preliminary Efficacy With AION-301 Administered by Intravenous Infusion Compared With Placebo Administered by Intravenous Infus

Sponsor: AION Healthspan, Inc. · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 36 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$2,991,320

Rescue Site Savings

+$1,975,400

Unlock Full NCT06721143 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06721143 Rescue Dossier →